Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to test the safety and efficacy of fondaparinux in patients with heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with HIT who are treated with fondaparinux experience a prompt and complete recovery of their platelet count, and the secondary objective is to determine if any new blood clots are formed while receiving the fondaparinux and up to one month after study enrollment. This information will be compared to a historical control.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00603824
Study type	Interventional
Source	Methodist Healthcare
Contact
Status	Withdrawn
Phase	Phase 4
Start date	January 2008
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00759083` - Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients	Phase 4
Completed	`NCT00412464` - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis	Phase 1
Completed	`NCT00456326` - Heparin-Induced Thrombocytopenia Registry	N/A
Terminated	`NCT00673439` - Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)	Phase 2
Active, not recruiting	`NCT00198575` - A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients	N/A
Completed	`NCT00283322` - Heparin Antibodies in Intensive Care Unit Patients (HAICU)	N/A
Not yet recruiting	`NCT05586854` - Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia	N/A
Not yet recruiting	`NCT03269019` - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia	N/A
Not yet recruiting	`NCT06066762` - Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Terminated	`NCT03809481` - Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban	Phase 3
Completed	`NCT05325346` - A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects	Phase 1
Recruiting	`NCT02717039` - Pharmacogenomics of Heparin-Induced Thrombocytopenia
Completed	`NCT02526485` - Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Completed	`NCT00748839` - Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical	N/A
Recruiting	`NCT05783895` - Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
Not yet recruiting	`NCT04782843` - Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
Completed	`NCT00198588` - Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia	Phase 3
Recruiting	`NCT04842760` - PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Terminated	`NCT01598168` - Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia	Phase 3
Completed	`NCT01654848` - Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients	N/A